Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations.

ABSTRACT:

Introduction

Clopidogrel is the most frequently utilized P2Y₁₂ inhibitor and is characterized by broad interindividual response variability resulting in impaired platelet inhibition and increased risk of thrombotic complications in a considerable number of patients. The potent P2Y₁₂ inhibitors, prasugrel and ticagrelor, can overcome this limitation but at the expense of an increased risk of bleeding. Genetic variations of the cytochrome P450 (CYP) 2 C19 enzyme, a key determinant in clopidogrel metabolism, have been strongly associated with clopidogrel response profiles prompting investigations of genetic-guided selection of antiplatelet therapy.

Areas covered

The present manuscript focuses on the rationale for the use of genetic testing to guide the sel

SUBMITTER: Galli M 

PROVIDER: S-EPMC9008593 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature